+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Heron Therapeutics Inc (HRTX) - Financial and Strategic SWOT Analysis Review

Heron Therapeutics Inc (HRTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Heron Therapeutics Inc (Heron) is a biotechnology company that uses proprietary polymer-based drug delivery platform to develop novel, patient-focused drugs for patients suffering from various types of cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, that improves the therapeutic profile of injectable pharmaceuticals. The company's marketed products include Sustol, an extended-release injection indicated in combination with other antiemetics in adults for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy (MEC); Cinvanti for chemotherapy-induced nausea and vomiting (CINV) prevention and Zynrelef (HTX-011) for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. Heron is headquartered in San Diego, California, the US.

Heron Therapeutics Inc Key Recent Developments

May 11, 2023: Heron Therapeutics announces financial results for the three months ended March 31, 2023 and highlights recent corporate updates
Apr 20, 2023: Heron Therapeutics Announces Commercial Leadership Changes
Apr 03, 2023: Heron Therapeutics Announces New CEO and Board Chairman
Mar 23, 2023: Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Heron Therapeutics Inc - Key Facts
  • Heron Therapeutics Inc - Key Employees
  • Heron Therapeutics Inc - Key Employee Biographies
  • Heron Therapeutics Inc - Major Products and Services
  • Heron Therapeutics Inc - History
  • Heron Therapeutics Inc - Company Statement
  • Heron Therapeutics Inc - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Company Overview
  • Heron Therapeutics Inc - Business Description
  • Product Category: Cinvanti
  • Overview
  • Performance
  • Product Category: Sustol
  • Overview
  • Performance
  • Product Category: Zynrelef
  • Overview
  • Performance
  • R&D Overview
  • Heron Therapeutics Inc - Corporate Strategy
  • Heron Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Heron Therapeutics Inc - Strengths
  • Heron Therapeutics Inc - Weaknesses
  • Heron Therapeutics Inc - Opportunities
  • Heron Therapeutics Inc - Threats
  • Heron Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Heron Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 11, 2023: Heron Therapeutics announces financial results for the three months ended March 31, 2023 and highlights recent corporate updates
  • Apr 20, 2023: Heron Therapeutics Announces Commercial Leadership Changes
  • Apr 03, 2023: Heron Therapeutics Announces New CEO and Board Chairman
  • Mar 23, 2023: Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates
  • Mar 10, 2023: Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023
  • Jan 09, 2023: Heron Therapeutics highlights progress in acute care and oncology care franchises
  • Nov 08, 2022: Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates
  • Aug 09, 2022: Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates
  • Jun 30, 2022: Heron Therapeutics announces restructuring and cost reduction plan to address market dynamics and prepare for long-term sustainability
  • May 09, 2022: Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Heron Therapeutics Inc, Key Facts
  • Heron Therapeutics Inc, Key Employees
  • Heron Therapeutics Inc, Key Employee Biographies
  • Heron Therapeutics Inc, Major Products and Services
  • Heron Therapeutics Inc, History
  • Heron Therapeutics Inc, Key Competitors
  • Heron Therapeutics Inc, Ratios based on current share price
  • Heron Therapeutics Inc, Annual Ratios
  • Heron Therapeutics Inc, Interim Ratios
  • Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Heron Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Heron Therapeutics Inc, Performance Chart (2018 - 2022)
  • Heron Therapeutics Inc, Ratio Charts
  • Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Pfizer Inc
  • Eisai Co Ltd
  • Mallinckrodt Pharmaceuticals Ltd
  • Merck & Co Inc
  • TerSera Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • Pacira BioSciences Inc
  • Aspen Pharmacare Canada Inc
  • Helsinn Therapeutics (US) Inc
  • Eisai Co Ltd
  • Mallinckrodt Pharmaceuticals Ltd
  • F. Hoffmann-La Roche Ltd
  • Pacira BioSciences Inc
  • ProStrakan Group plc
  • Fresenius Kabi USA LLC
  • TerSera Therapeutics LLC
  • Merck & Co Inc
  • Pfizer Inc
  • Helsinn Therapeutics (US) Inc
  • Aspen Pharmacare Canada Inc
  • GSK plc
  • ProStrakan Group plc
  • Fresenius Kabi USA LLC
  • GSK plc